R C Bonadonna

Summary

Country: Italy

Publications

  1. ncbi Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study
    Riccardo C Bonadonna
    Division of Endocrinology and Metabolism, Department of Medicine, University of Verona School of Medicine, Verona, Italy
    J Clin Endocrinol Metab 95:5028-36. 2010
  2. ncbi Intracellular partition of plasma glucose disposal in hypertensive and normotensive subjects with type 2 diabetes mellitus
    E Bonora
    Division of Endocrinology and Metabolic Diseases, University of Verona Medical School, Verona, Italy
    J Clin Endocrinol Metab 86:2073-9. 2001
  3. ncbi Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control
    E Bonora
    Division of Endocrinology and Metabolic Disease, University of Verona Medical School, Verona, Italy
    Diabetes Care 24:2023-9. 2001
  4. ncbi Variants and haplotypes of TCF7L2 are associated with ?-cell function in patients with newly diagnosed type 2 diabetes: the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 1
    S Bonetti
    Department of Medicine, University of Verona, Verona, Italy
    J Clin Endocrinol Metab 96:E389-93. 2011
  5. ncbi Assessment of beta-cell function during the oral glucose tolerance test by a minimal model of insulin secretion
    A Cretti
    University of Verona School of Medicine, Verona, Italy
    Eur J Clin Invest 31:405-16. 2001
  6. ncbi Relation between soluble adhesion molecules and insulin sensitivity in type 2 diabetic individuals: role of adipose tissue
    G Targher
    Division of Endocrinology and Metabolic Diseases, University of Verona Medical School, Verona, Italy
    Diabetes Care 24:1961-6. 2001
  7. ncbi The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study
    E Bonora
    Division of Endocrinology and Metabolic Diseases, University of Verona Medical School, Verona, Italy
    Diabet Med 21:52-8. 2004
  8. ncbi Variants of GCKR affect both ?-cell and kidney function in patients with newly diagnosed type 2 diabetes: the Verona newly diagnosed type 2 diabetes study 2
    Sara Bonetti
    Department ofMedicine, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
    Diabetes Care 34:1205-10. 2011

Collaborators

Detail Information

Publications8

  1. ncbi Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study
    Riccardo C Bonadonna
    Division of Endocrinology and Metabolism, Department of Medicine, University of Verona School of Medicine, Verona, Italy
    J Clin Endocrinol Metab 95:5028-36. 2010
    ..Glucokinase plays a key role in glucose homeostasis. Glucokinase activators can lower glucose levels in both animal and human type 2 diabetes, but their mechanism of action has never been explored in humans...
  2. ncbi Intracellular partition of plasma glucose disposal in hypertensive and normotensive subjects with type 2 diabetes mellitus
    E Bonora
    Division of Endocrinology and Metabolic Diseases, University of Verona Medical School, Verona, Italy
    J Clin Endocrinol Metab 86:2073-9. 2001
    ..These results indicate that hypertension markedly aggravates insulin resistance featuring type 2 diabetes mellitus. The molecular defects underlying this phenomenon involve primarily GS...
  3. ncbi Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control
    E Bonora
    Division of Endocrinology and Metabolic Disease, University of Verona Medical School, Verona, Italy
    Diabetes Care 24:2023-9. 2001
    ..To evaluate the extent of plasma glucose excursions with meals, the relations between plasma glucose levels at different times of the day, and the relations between the latter and HbA(1c) in non-insulin-treated type 2 diabetic subjects...
  4. ncbi Variants and haplotypes of TCF7L2 are associated with ?-cell function in patients with newly diagnosed type 2 diabetes: the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 1
    S Bonetti
    Department of Medicine, University of Verona, Verona, Italy
    J Clin Endocrinol Metab 96:E389-93. 2011
    ..Intronic variants of TCF7L2 are confirmed genetic risk factors for type 2 diabetes and are associated to alterations in beta cell function in nondiabetic individuals...
  5. ncbi Assessment of beta-cell function during the oral glucose tolerance test by a minimal model of insulin secretion
    A Cretti
    University of Verona School of Medicine, Verona, Italy
    Eur J Clin Invest 31:405-16. 2001
    ..542, P < 0.02). CONCLUSIONS: Analogically modelling beta-cell function during the OGTT provides a simple, useful tool for the physiological assessment of beta-cell function...
  6. ncbi Relation between soluble adhesion molecules and insulin sensitivity in type 2 diabetic individuals: role of adipose tissue
    G Targher
    Division of Endocrinology and Metabolic Diseases, University of Verona Medical School, Verona, Italy
    Diabetes Care 24:1961-6. 2001
    ..These findings support the possibility that adipose tissue releases one or more factors that may adversely affect endothelial function on one hand and insulin sensitivity on the other...
  7. ncbi The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study
    E Bonora
    Division of Endocrinology and Metabolic Diseases, University of Verona Medical School, Verona, Italy
    Diabet Med 21:52-8. 2004
    ..To evaluate the cardiovascular risk associated with the presence of the Metabolic Syndrome in Type 2 diabetic subjects...
  8. ncbi Variants of GCKR affect both ?-cell and kidney function in patients with newly diagnosed type 2 diabetes: the Verona newly diagnosed type 2 diabetes study 2
    Sara Bonetti
    Department ofMedicine, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
    Diabetes Care 34:1205-10. 2011
    ..We tested whether GCKR variability affects type 2 diabetes or kidney-related phenotypes in newly diagnosed type 2 diabetes...